Study type

Study topic

Disease /health condition

Study type

Non-interventional study
Study drug and medical condition

Study drug International non-proprietary name (INN) or common name

DULAGLUTIDE
EXENATIDE
LIRAGLUTIDE
SEMAGLUTIDE
TIRZEPATIDE

Anatomical Therapeutic Chemical (ATC) code

(A10BJ05) dulaglutide
dulaglutide
(A10BJ01) exenatide
exenatide
(A10BJ02) liraglutide
liraglutide
(A10BJ06) semaglutide
semaglutide
(A10BX16) tirzepatide
tirzepatide

Medical condition to be studied

Medullary thyroid cancer
Population studied

Age groups

  • Adult and elderly population (≥18 years)
    • Adults (18 to < 65 years)
      • Adults (18 to < 46 years)
      • Adults (46 to < 65 years)
    • Elderly (≥ 65 years)
      • Adults (65 to < 75 years)
      • Adults (75 to < 85 years)
      • Adults (85 years and over)

Estimated number of subjects

6750
Study design details

Main study objective

Systematically monitor the annual incidence of MTC through North American Association of Central Cancer Registries (NAACCR) to identify any possible increase related to the introduction of long-acting GLP-1 RAs.
Establish a registry of incident cases of MTC in order to characterize their medical histories and possible risk factors, including history of treatment with long-acting GLP-1 RAs.

Outcomes

A record of medullary thyroid carcinoma (MTC) identified from the US state/regional population-based cancer registries

Data analysis plan

Descriptive statistics will be used to characterize potential risk factors, including drug exposures, radiation exposure, lifestyle factors, environmental exposures, and other characteristics (including family history of MEN syndromes or FMTC history).
Exposure to long-acting GLP-1 RAs will be characterized by dose and duration of exposure prior to the diagnosis of MTC.